ATRC
$29.18+0.14 (+0.50%)
AtriCure, Inc.
Recent News
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.
AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates
AtriCure (NASDAQ:ATRC) CFO Angie Wirick outlined the company’s early expectations for 2026 growth and discussed product adoption trends across its cardiac surgery and pain management franchises during an appearance at the Citizens Life Sciences Conference. Initial 2026 outlook: 12% to 14% organic g